INSM1 inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of Insulinoma-Associated 1 (INSM1), a zinc-finger transcription factor that plays a crucial role in neuroendocrine differentiation and development. INSM1 is predominantly expressed in the developing nervous system and various neuroendocrine tissues, where it functions as a transcriptional repressor, regulating the expression of genes involved in cell cycle control, differentiation, and the maintenance of neuroendocrine identity. By binding to specific DNA sequences, INSM1 can repress or activate the transcription of target genes, influencing the fate and function of neuroendocrine cells. Inhibiting INSM1 allows researchers to explore its role in these processes and to study the molecular mechanisms by which it controls neuroendocrine development and differentiation.
In research, INSM1 inhibitors are valuable tools for investigating the complex networks of gene regulation that govern neuroendocrine cell differentiation and function. By blocking INSM1 activity, scientists can examine how the inhibition of this transcription factor affects the expression of its target genes and the subsequent impact on cellular differentiation, proliferation, and maturation. These inhibitors provide insights into the specific pathways and regulatory circuits that INSM1 influences, helping to clarify its role in the development of the neuroendocrine system. Additionally, INSM1 inhibitors can be used to study the broader implications of transcriptional repression in neuroendocrine cells, including the interplay between INSM1 and other transcription factors or signaling molecules that contribute to neuroendocrine identity and function. Through these studies, the use of INSM1 inhibitors enhances our understanding of the molecular mechanisms underlying neuroendocrine differentiation, the role of transcriptional regulation in cellular development, and the critical functions of INSM1 in maintaining the specialized characteristics of neuroendocrine cells.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Another histone deacetylase inhibitor, it can alter chromatin structure and affect INSM1 expression. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
A histone deacetylase inhibitor, it impacts chromatin remodeling and may influence INSM1. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor, it can affect DNA methylation and possibly INSM1 expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Similar to 5-Azacytidine, it affects DNA methylation, potentially influencing INSM1 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, it can influence pathways related to differentiation and potentially INSM1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, it may affect signaling pathways that influence INSM1 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor, potentially influencing pathways that regulate INSM1 expression. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
Inhibits the TGF-β pathway, which could be involved in regulating INSM1 expression. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
A γ-secretase inhibitor, affecting Notch signaling which might influence INSM1 expression. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
A MDM2 inhibitor, it can indirectly affect p53-mediated pathways and potentially INSM1 expression. | ||||||